Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,245 across all filing types
Latest filing 2022-11-09 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Pursuant to the provision of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the extract copies of newspaper ....
Interim / Quarterly Report Classification · 95% confidence The document is a communication addressed to stock exchanges (NSE and BSE) regarding the publication of unaudited financial results for the quarter and half year ended September 30, 2022. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of financial results. The document includes extracts of newspaper advertisements of these unaudited financial results. The presence of detailed financial figures for the quarter and half year, including total income, profit before tax, net profit, and equity share capital, indicates substantive financial data is included. The document is not merely an announcement that a report is published or attached, but contains actual financial results data. Therefore, this is a financial report for a period shorter than a full fiscal year, specifically an interim/quarterly report.
2022-11-09 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Bliss GVS Pharma Ltd. dated November 07, 2022, addressed to stock exchanges, reporting the outcome of a Board Meeting. It specifically mentions the approval of unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2022. The document includes extensive financial data such as revenue, expenses, profit before tax, tax expenses, and net profit for the period, both standalone and consolidated. The presence of unaudited financial results for a quarter and half year period, along with detailed financial statements, indicates this is a comprehensive interim or quarterly financial report. The document is not merely an announcement of a report publication but contains substantive financial data and analysis. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-11-07 English
We would like to inform you that, Board Meeting of the Company was held today i.e. Monday, November 07, 2022 at the registered office of the Company. In pursuant to Regulation 30 and 33 ....
Interim / Quarterly Report Classification · 95% confidence The document is a communication from Bliss GVS Pharma Ltd. to stock exchanges regarding the outcome of a Board Meeting held on November 7, 2022. It specifically mentions the approval of the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2022. The document includes detailed financial data such as revenue, expenses, profit before tax, and net profit for the period, indicating substantive financial information rather than a mere announcement or summary. The presence of unaudited financial results for a quarter and half year period aligns with the characteristics of an Interim / Quarterly Report (IR). The document is not a brief announcement or a certification letter, but contains actual financial statements and analysis for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2022-11-07 English
Board Meeting — Financial results
Board/Management Information Classification · 95% confidence The document is a formal notification addressed to stock exchanges about an upcoming Board Meeting scheduled for November 7, 2022. The purpose of the meeting is to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ending September 30, 2022. The document also mentions the closure of the trading window for insiders in compliance with SEBI regulations. The document is short (1912 characters) and serves as an announcement of a future event (Board Meeting) rather than containing any financial results or detailed report itself. It does not contain actual financial data or detailed management discussion. Therefore, it is best classified as a Board/Management Information (MANG) filing, which covers announcements related to board meetings and management activities.
2022-10-29 English
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2022 ,inter alia, to consider and approve the Unaudited Standalone ....
Board/Management Information Classification · 95% confidence The document is a formal notification addressed to stock exchanges about an upcoming Board Meeting scheduled for November 7, 2022. The purpose of the meeting is to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ending September 30, 2022. The document also mentions the closure of the trading window for insiders in compliance with SEBI regulations. The document is short (1912 characters) and serves as an announcement of a future event (Board Meeting) rather than containing any financial results or detailed management discussion. It does not contain actual financial data or detailed report content. Therefore, it is best classified as a Board/Management Information filing, which covers announcements related to board meetings and management activities.
2022-10-29 English
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform your good office regarding the inclusion of new names ....
Major Shareholding Notification Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (NSE and BSE) regarding changes in the category of Promoter/Promoter Group of the company Bliss GVS Pharma Limited. It lists names and shareholding percentages of promoters and promoter group members. The document references SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events or information. This type of filing is an announcement about changes in significant share ownership or promoter group composition, which aligns with the category of Major Shareholding Notification (MRQ). The document is short (1720 characters) and does not contain financial statements or detailed financial data, so it is not an Annual Report or Interim Report. It is not a voting result, board change, or other categories. Therefore, the best fit is Major Shareholding Notification (MRQ).
2022-10-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.